Page 9 - Andrewj Barwicki News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 05, 2021 NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) Anavex Life Sciences Corp.  . (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senior Vice President for Nonclinical Development. Dr. Laniyonu has over 24 years’ experience with the US Food and Drug Administration (FDA). “Dr. Laniyonu has an accomplished track record of working within the FDA,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “His depth of experience makes him an excellent choice to provide objective perspective and manage the continuous nonclinical projects at Anavex.”

United kingdomChristopheru misslingAdebayo bayo laniyonuAndrewj barwickiCompany nasdaqAward for distinguished serviceResearch business developmentAdvisory committeeNonclinical developmentGroup recognition awardAnavex life sciences corpDepartment of healthOutstanding service awardHuman servicesDrug administrationUniversity of glasgow